NCT07889570Completed
A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
This is a randomized, controlled, hybrid clinical trial evaluating the effects of the Evolv GLP-1 supplement on weight loss, blood sugar regulation, and appetite suppression over 12 weeks. Participants are randomized to either the intervention group (8 capsules daily) or a control group receiving standardized healthy eating guidance from the American Diabetes Association. The study enrolls 98 male and female participants aged 18 and older with a BMI of 25-29.9 kg/m2. Primary endpoints include Hemoglobin A1c (HgbA1c) measured via bloodwork at Baseline, Week 6, and Week 12, as well as body weight and waist circumference measurements collected at Baseline, Week 4, Week 6, Week 8, and Week 12. Secondary endpoints capture participant perceptions of appetite suppression, weight loss, blood sugar, and overall well-being via self-reported questionnaires at the same time points.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 98 (actual)
- First submitted
- 16 Oct 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- Evolv
- Diseases
- Obesity
- NCT number
- NCT07889570
What you commit to
- Study type: Interventional
- Participants enrolled: 98
- From 1 Apr 2026 to the primary completion date, 1 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Anyone who has been treated with any antibiotic or antifungal prescription medication in the last 2 months (8 weeks)
- Heavy drinkers or drug users (a heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week)
Other illness
- Diagnosed with Type 1 diabetes, any metabolic or endocrine disorder, or any disorder that affects blood sugars (e.g., hypothyroidism, Hashimoto's thyroiditis)
- Diagnosed with Type 2 diabetes mellitus (T2DM) and have been prescribed metformin, insulin, Sulfonylureas, Meglitinides, SGLT2 inhibitors and/or GLP-1 medications including Wegovy, Ozempic, Rybelsus, Saxenda, Victoza, Zepbound, Byetta, Bydureon, Trulicity, or Adlyxin
- Current use or past history of use within the last 2 months (8 weeks) of corticosteroids including Deltasone, Orapred, Prelone, Medrol, Qvar, Celestone, Decadron, Cortef, or Kenalog
- Current use or past history of use within the last 2 months (8 weeks) of immunosuppressants including Tacrolimus (Prograf), Cyclosporine (Neoral), or Sirolimus (Rapamune)
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including cancer, liver, and psychiatric disorders
- Has had any major illness in the last three months
- Anyone with known severe allergic reactions, including those requiring the use of an Epi-pen
- Anyone with any allergies or sensitivities to any of the study product ingredients
- Anyone with a history of substance abuse
Other
- Is currently undergoing or planning to undergo any significant medical procedures in the next six months
- Anyone who has undergone any surgeries or invasive treatments in the last six months, or has any planned during the study period
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
- Anyone unwilling to follow the study protocol
- Anyone who is currently a smoker or has been a smoker in the past 3 months
Who the study is looking for
- Be male or female
- Be aged 18+
- BMI of 25-29.9 kg/m2
- Anyone with concerns regarding all of the following for the past 12 weeks: weight management and food cravings and/or appetite management
- Must not be living with any uncontrolled chronic disease
- Not currently taking, and not planning to take for the duration of the test period, any products, prescription medications, herbal remedies, over-the-counter medications, or supplements that target blood sugar regulation, weight, or appetite
- Willing to maintain their current sleep schedule and activity level for the duration of the study
- Resides in the United States
- Not currently partaking in another research study and will not be partaking in any other research study for the next 12 weeks or at any point during this study's duration
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Citruslabs Coordinator of this site? Confirm its status | Las Vegas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.